EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Efficacy and Safety of Oral Oseltamivir for Influenza Prophylaxis in Transplant Recipients

Michael G Ison, Peter Szakaly, Michael Y Shapira, Gergely Kriván, Ann Nist, Regina Dutkowski

Antiviral Therapy · 2012-08 · 17 (6) · 955-964

DOI: 10.3851/imp2192 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Antiviral Therapy, online erschienen am 01.08.2012. Verfasst von Michael G Ison und 5 weiteren Autor:innen. Beteiligte Einrichtung: Divisions of Infectious Diseases and Organ Transplantation, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. mgison@northwester…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Kidney Transplantation, Liver Transplantation. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Haematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) recipients are at high risk for severe influenza and its complications, and may not be adequately protected by vaccination.

Methods

Liver, kidney, or liver–kidney transplant or allogeneic HSCT recipients aged ≥1 year were randomized to oseltamivir (75 mg once daily for those ≥13 years or weight-based dosing for children 1–12 years) or placebo for 12 weeks during periods of local influenza circulation. Patients were assessed for influenza infection via daily diary, every-other-week culture and PCR, and baseline and end-of-treatment serology.

Results

A total of 477 subjects were enrolled (239 oseltamivir and 238 placebo); most were adults (96%) and SOT recipients (81%). In the intent-to-treat population, the frequency of laboratory-confirmed clinical influenza (culture positive and/or >4-fold increase in haemagglutinin antibody inhibition [primary end point]) was similar in the oseltamivir and placebo groups (2.1% [5/237] and 2.9% [7/238]). Incidence of laboratory-confirmed influenza was significantly reduced in the oseltamivir group versus placebo when determined by reverse transcriptase-PCR (1.7% [4/237] versus 8.4% [20/238]; 95% CI 2.8, 11.1) or viral culture (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationKidney TransplantationLiver TransplantationAdministration, OralAdolescentAdultAgedAntiviral AgentsChildChild, PreschoolFemaleHumansIncidenceInfantInfluenza A Virus, H1N1 SubtypeInfluenza, HumanMaleMiddle AgedOseltamivirProspective StudiesReverse Transcriptase Polymerase Chain ReactionYoung Adult

Substanzen

Antiviral AgentsOseltamivir

Autor:innen und Institutionen

  • Divisions of Infectious Diseases and Organ Transplantation, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. mgison@northwestern.edu

Zitieren

APA

Ison, M. G., Szakaly, P., Shapira, M. Y., Kriván, G., Nist, A., & Dutkowski, R. (2012). Efficacy and Safety of Oral Oseltamivir for Influenza Prophylaxis in Transplant Recipients. Antiviral Therapy, 17(6), 955-964. https://doi.org/10.3851/imp2192

Vancouver

Ison MG, Szakaly P, Shapira MY, Kriván G, Nist A, Dutkowski R. Efficacy and Safety of Oral Oseltamivir for Influenza Prophylaxis in Transplant Recipients. Antiviral Therapy. 2012;17(6):955-964. doi:10.3851/imp2192

BibTeX
@article{Ison2012,
  author = {Ison, Michael G and Szakaly, Peter and Shapira, Michael Y and Kriván, Gergely and Nist, Ann and Dutkowski, Regina},
  title = {Efficacy and Safety of Oral Oseltamivir for Influenza Prophylaxis in Transplant Recipients},
  journal = {Antiviral Therapy},
  year = {2012},
  volume = {17},
  number = {6},
  pages = {955--964},
  doi = {10.3851/imp2192}
}
Kostenlos starten →